Azvudine vs Doravirine/islatravir (Idvynso)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Azvudine · FNC

Marketed by Henan Genuine Biotech

Phase 3 in HIVsmall molecule
Partial signal

NCT04303598 · Phase 3 · status unknown

This is a randomized, double-blind, active-controlled trial testing whether azvudine achieves viral suppression as well as an established comparator, using a recognized clinical measure of HIV control, but results are not yet posted so the outcome is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Reported efficacy

Evaluation of azivudine tablet (FNC) combined with reverse transcriptase inhibitor therapy without anti-hiv treatment. (At 48 weeks); Preliminary evaluation of the efficacy of azivudine tablets (FNC) combined with reverse transcriptase inhibitors in the treatment of patients who have not received anti-hiv treatment. (At 48 weeks): 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05) (unclear)

Result source: NCT04109183

Doravirine/islatravir (Idvynso)

Marketed by Merck & Co.

Approved in HIVsmall molecule
Partial signal

NCT05631093 · Phase 3 · active, not recruiting

Trial 051 randomized 551 virologically suppressed adults with HIV-1 2:1, open-label, to switch to once-daily doravirine/islatravir or stay on their baseline antiretroviral regimen. The primary efficacy endpoint was the proportion with HIV-1 RNA at or above 50 copies/mL at Week 48, tested for non-inferiority with a 4-percentage-point margin. The rate was 1.4% after the switch and 4.9% on baseline therapy (difference -3.58, 95% CI -7.81 to -0.77), so non-inferiority was shown and the primary endpoint was met. The other registered primaries are adverse-event rates. Source: ClinicalTrials.gov posted results and the IDVYNSO US label, section 14.

Next expected readout: May 2029 · NCT04776252 (registry estimate)

Reported efficacy

Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48; Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48; Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). (met)

Result source: NCT05630755

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAzvudineDoravirine/​islatravir (Idvynso)
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Trial running · NCT05630755
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Trial running · NCT05630755
CD4 count, change (week 48)—Not reported—Trial running · NCT05630755

HIV-1 RNA below 50 copies/mL (week 48)

Azvudine
—Not reported
Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755

HIV-1 RNA 50 copies/mL or more (week 48)

Azvudine
—Not reported
Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755

CD4 count, change (week 48)

Azvudine
—Not reported
Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Azvudine
符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05) NCT04109183 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result
Doravirine/islatravir (Idvynso)
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3% NCT04233879 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=366) vs staying on baseline ART (n=185): 1.4% vs 4.9%; difference -3.58 percentage points (95% CI -7.81 to -0.77), non-inferiority p < 0.001 against a 4-point margin (CT.gov posted results). NCT05631093 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). NCT05630755 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48 (Week 48): Group 1: Doravirine/Islatravir (DOR/ISL) 0% vs Group 2: Baseline Antiretroviral Therapy (ART) 1.5% NCT04223778 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Week 48 HIV-1 RNA ≥50 copies/mL: 0.6% DOR/ISL vs 0.3% BIC/FTC/TAF; treatment difference 0.31 percentage points (95% CI -1.19 to 1.96; p<.001); prespecified non-inferiority margin was 4 percentage points. NCT04223791 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azvudine's landscape · Doravirine/islatravir (Idvynso)'s landscape